{
  "id": 10718655,
  "title": "Current Challenges in CAR T Manufacturing",
  "url": "https://urgent.news/2026/09/29/current-challenges-in-car-t-manufacturing",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-29T15:13:30.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/bioprocessing/current-challenges-in-car-t-manufacturing/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The article discusses the challenges in manufacturing CAR T therapies, which have transitioned from experimental treatments to clinically validated therapies with a $6 billion global market. The primary bottleneck in manufacturing is scalability, driven by donor-to-donor variability, patient-specific production, and complex multi-step workflows within tightly controlled GMP environments. These factors increase costs, create process variability, and limit manufacturing throughput, ultimately restricting patient access to these life-saving therapies. Additionally, existing analytical approaches are limited in real-time prediction of manufacturing outcomes, relying on downstream or metabolite-based measurements that do not provide insights into what a cell can become. To address these challenges, Cytomos has developed AuraCyt, a predictive cell intelligence platform that uses dielectric spectroscopy to reveal cellular states earlier in the manufacturing process, enabling informed intervention and a transition from reactive to proactive process control.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}